SCHEMBL21362021

SCHEMBL21362021

COc1cc(C(O)c2ccc(F)cc2)c(Br)cc1F

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.38
GAA P10253 1/20 0.37
TOP2A P11388 1/20 0.37
TOP2B Q02880 1/20 0.37
P2RX7 Q99572 1/20 0.36
LMNA P02545 2/20 0.33
THRA P10827 1/20 0.33
THRB P10828 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
NFE2L2 Q16236 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20157860 0.87 PDE10A (0.38) ACHEGAATOP2ATOP2BLMNA
SCHEMBL21362715 0.86 TRPA1 (0.40) GAATOP2ATOP2B
SCHEMBL20157890 0.86 OPRK1 (0.35) GAATOP2ATOP2BHTT
SCHEMBL11857823 0.79 APLNR (0.44) ACHEGAALMNATHRATHRB
SCHEMBL24826176 0.78 MGAM (0.40) GAALMNACYP1A2CYP3A4CYP2C9
SCHEMBL20157585 0.78 LMNA (0.45) GAALMNATHRATHRBNFE2L2
SCHEMBL21352143 0.77 BRD4 (0.34) THRATHRB
SCHEMBL17633584 0.77 TOP2A (0.47) ACHEGAATOP2ATOP2BLMNA
SCHEMBL21830940 0.76 NFE2L2 (0.38) ACHEGAALMNANFE2L2CYP3A4
SCHEMBL29922538 0.76 NFE2L2 (0.38) ACHEGAALMNANFE2L2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF MYC, BRD1, BRD3 ACHE 4557/4885GAA 4852/4885TOP2A 3871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.